Touch Medical Media Services's video: Othman Al Sawaf ASCO20: Results of the Phase III CLL14 Trial for Chronic Lymphocytic Leukaemia

We were delighted to speak to Othman Al-Sawaf to discuss the data presented at ASCO20 Virtual Scientific Programme on the phase III CLL14 trial, which found that the BCL2 inhibitor venetoclax plus the monoclonal antibody obinutuzumab prolonged progression-free survival vs obinutuzumab and chlorambucil in patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions. Questions 1. What are the limitations of the current standard of care for previously untreated chronic lymphocytic leukaemia? (0:06) 2. What is the rationale for the use of fixed-duration treatment with venetoclax and obinutuzumab in this treatment setting? (1:16) 3. Could you give us an overview of the CLL14 trial and its impact on clinical practice? (2:22) 4. What have the latest findings taught us about the long-term efficacy and safety of this combination? (3:52) 5. In which patients will this combination be most beneficial and in whom is it contraindicated? (6:00) Speaker disclosure: Othman Al-Sawaf has no financial or non-financial conflicts of interest to declare in relation to this video. Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group. Filmed in coverage of the 2020 ASCO Virtual Scientific Program.